KROS Stock Analysis: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$9.96
-0.11 (-1.09%)
▼
5d:
-2.45%
30d:
-11.55%
90d:
-13.32%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $9.96, which is considered oversold relative to its 30-day fair value range of $10.14 to $11.30.
Technical Outlook: Technically, KROS is in a downtrend. The price is currently testing key support at $9.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KROS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.83 (+116.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KROS is in a downtrend. The price is currently testing key support at $9.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KROS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.83 (+116.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.14 -
$11.30
Company Quality Score
48/100
(HOLD)
Options IV Signal
39th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 39th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 116.8% below Wall St target ($21.83)
Trading Range Analysis
30-Day Trading Range
$10.14 -
$11.30
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.04
(10.5%)
Support & Resistance Levels
Support Level
$9.83
Resistance Level
$10.68
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.80
Wall Street Target
$21.83
(+116.8%)
Revenue Growth (YoY)
-99.8%
Profit Margin
-256.6%
Share & Embed Analysis
Last updated: August 03, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jean Jacques Bienaime
BUY
1000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
